NICE Approves Ruxolitinib Cream for Treating Vi...

By HEOR Staff Writer

February 25, 2026

NICE Backs Ruxolitinib Cream Vitiligo Treatment Ruxolitinib cream vitiligo therapy has received a major endorsement from the National Institute for Health and Care Excellence (NICE), w...
Enhancing Early-Stage Cancer Treatment: Overcoming Barriers for Better Outcomes
EU Launches Joint Scientific Consultations to Enhance Health Technology Asses...
NHS Cost-Effectiveness Thresholds Boost Drug Approvals and Innovation
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft ...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before...
NICE NHS Prioritization: A Strategic Shift to Address Healthcare Challenges
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
Paving the Way for Digital Health Technologies: NICE’s Bold New Strateg...
NICE Kidney Cancer Guideline: Enhancing Biopsy Use to Minimize Unnecessary Su...
NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival
Assessment of Glofitamab With Gemcitabine in DLBCL Reveals No Additional Benefit